Paul‐Egbert Reimitz

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial

Pascal Vranckx, Marco Valgimigli, Lars Eckardt et al. · The Lancet · 2019 · 636 citations

Thrombosis, Percutaneous Coronary Intervention, Cardiovascular Disease +13

The Inventory of Depressive Symptomatology (IDS): Clinician (IDS‐C) and Self‐Report (IDS‐SR) ratings of depressive symptoms

A. John Rush, Thomas Carmody, Paul‐Egbert Reimitz · International Journal of Methods in Psychiatric Research · 2000 · 430 citations

Mental Health, Psychology, Social Sciences +19

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial

Stefan H. Hohnloser, A. John Camm, Riccardo Cappato et al. · European Heart Journal · 2019 · 168 citations · Full text

Cardiovascular Pharmacology, Edoxaban Therapy, Pharmacotherapy +18

Mirtazapine versus amitriptyline in the long-term treatment of depression

Stuart Montgomery, Paul‐Egbert Reimitz, M. Zivkov · International Clinical Psychopharmacology · 1998 · 121 citations

Psychotropic Medication, Psychopharmacology, Pharmacotherapy +16

Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial

Pascal Vranckx, Thorsten Lewalter, Marco Valgimigli et al. · American Heart Journal · 2017 · 86 citations · Full text